$GENB

Generate Biomedicines, Inc.

Generate Biomedicines develops protein therapeutics using machine learning for drug discovery and development. Its investigational products include GB-0895, an anti-TSLP antibody for severe asthma; GB-4362, an antibody designed to neutralize an MMAE payload; and GB-5267, a MUC16 CAR-T cell therapy. The company also develops the Generate Platform, which combines computational methods with scalable biohardware across therapeutic areas and protein modalities. Generate Biomedicines is based in Somerville, Massachusetts.

1
0
4
—
$185K
ARNOLD FRANCES
100%
See all $GENB insider activity →

Generate Biomedicines Reports Third Quarter 2026 Financial Results and Provides Business Update

Generate Biomedicines, Inc. (GENB) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Generate Biomedicines Reports Third Quarter 2026 Financial Results and Provides Business Update GB-0895 is being evaluated in two Phase 3 severe asthma studies for dosing twice a year A single dose of GB-0895 produced sustained pharmacological activity for at least s

GENB sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 5 news stories mentioning GENB (Generate Biomedicines, Inc.). Coverage has skewed bearish: 1 bullish, 0 neutral, and 4 bearish.

Recent GENB coverage spans earnings, financial news and technology.

In the last 30 days, GENB insiders filed 1 SEC Form 4 transaction — no purchases and 1 sale ($185K). The most active reporter was ARNOLD FRANCES with 1 filing. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.

What's driving GENB

AlphAI scores every news story that mentions GENB with an AI model for sentiment and relevance, and aggregates insider trades from Generate Biomedicines, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $GENB

Score
$GENBHighAI 8/10Earnings

Generate Biomedicines Reports Third Quarter 2026 Financial Results and Provides Business Update

Generate Biomedicines, Inc. (GENB) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Generate Biomedicines Reports Third Quarter 2026 Financial Results and Provides Business Update GB-0895 is being evaluated in two Phase 3 severe asthma studies for dosing twice a year A single dose of GB-0895 produced sustained pharmacological activity for at least s

Roswell Park, Generate Biomedicines Launch Exclusive Clinical Trial of ‘Armored’ CAR T Therapy for Ovarian Cancer

Roswell Park and Generate Biomedicines (NASDAQ: GENB) announced the first patient has been dosed in a phase 1 clinical trial for GB-5267, an AI-engineered CAR T-cell therapy targeting MUC16 in ovarian cancer. The trial aims to evaluate the safety and tolerability of GB-5267, which is designed to avoid pre-infusion chemotherapy and its side effects. GB-5267 targets a biomarker over-expressed in over 80% of ovarian tumors, aiming to optimize T-cell function in solid tumors.

Biotech Stocks At 52-Week Highs - GENB +15%, BDSX +10%, CDNA +6%, CPIX +10%, CRDL +7%

Several biotech stocks hit 52-week highs on August 25, 2026. Generate Biomedicines (GENB) rose 15% to $22.67, despite a wider net loss. Biodesix (BDSX) climbed 10% to $30, reporting a 34% revenue increase. CareDx (CDNA) gained 6%, with Medicare coverage for its transplant tests. Cumberland Pharmaceuticals (CPIX) rose 10% to $8.70, advancing Ifetroban in trials. Cardiol Therapeutics (CRDL) increased 7% to $2.02, with CardiolRx in Phase 3 trials.

$GENBMedEarnings

Generate Biomedicines Inc. Reports Second Quarter 2026 Financial Results and Provides Business Update

Generate Biomedicines, Inc. (GENB) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Generate Biomedicines Inc. Reports Second Quarter 2026 Financial Results and Provides Business Update SOLAIRIA-1 AND SOLAIRIA-2 Phase 3 studies for GB-0895 (anti-TSLP) in severe asthma continue to advance with recruitment underway across all six global regions Phase

Nvidia CEO Jensen Huang Said AI's "Most Profound Impact Will Be in Life Sciences." Does This Bet on a Biotech Stock Prove He Means It?

Nvidia (NVDA) said AI’s “most profound impact” will be in life sciences and announced an AI co-innovation lab with Eli Lilly, targeting up to $1 billion over five years. Nvidia’s May 13F showed it owned 833,000+ shares of Generate Biomedicines (GENB), valued at about $10.4 million as of Q1 end. The article links Nvidia’s AI push to its biotech investment.

Nvidia Owns This Under-the-Radar $20 Stock Poised to Disrupt a $1.8 Trillion Market

Nvidia, through its venture arm NVentures, owns 833,325 shares of Generate Biomedicines (NASDAQ: GENB), according to the article. The stake totals about $13 million, and Generate Biomedicines is a pre-profit biotech developing an AI platform for virtual drug testing; four candidates are in its pipeline, including one in Phase 3 for severe asthma (GB-0895). The piece cites estimates that drug development can take 10–15 years and about $2.6 billion per approved medicine.

Related tickers